Department of Hematology and Oncology, Stavanger University Hospital, Stavanger, Norway.
Ann Surg Oncol. 2012 Nov;19(12):3719-26. doi: 10.1245/s10434-012-2454-8. Epub 2012 Jul 3.
To investigate the prognostic value of occult metastases detected by quantitative measurements of candidate biomarkers in sentinel lymph nodes (SLNs) from patients curatively resected for colon cancer.
Resection specimens from consecutive patients undergoing surgery for localized colon cancer were subjected to ex vivo SLN mapping. SLNs were examined for the presence of metastases by routine hematoxylin-erythrosin-safranin staining and by cytokeratin 20 (CK20) and mucin 2 (MUC2) mRNA quantification. The patients were stratified according to KRAS and BRAF mutation status and microsatellite instability status in their primary tumors. Survival end points were analyzed by Kaplan-Meier survival estimates and log-rank tests.
A total of 817 SLNs were identified in 206 (97 %) of the 213 included patients. Routine histological examination of SLNs and other regional lymph nodes identified 63 patients with positive nodes (pN+), of which 42 (67 %) were positive in one or more SLNs (sensitivity 67 %, false-negative rate 33 %). On the basis of the CK20 and MUC2 mRNA levels in SLNs, occult metastases were suggested in 86 (60 %) and 52 (36 %) of the 143 otherwise LN-negative (pN0) patients, respectively. Survival analysis with a median 3.6-year follow-up revealed that MUC2 mRNA quantification had significant prognostic value in SLNs from all patients; however, occult SLN metastasis detection did not.
Occult SLN metastases detected by CK20 and MUC2 mRNA quantification had limited prognostic value.
研究通过定量测量前哨淋巴结(SLN)中候选生物标志物来检测隐匿性转移在接受结肠癌根治性切除患者中的预后价值。
对连续接受局部结肠癌手术的患者的切除标本进行体外 SLN 定位。通过常规苏木精-伊红-番红染色和细胞角蛋白 20(CK20)和黏蛋白 2(MUC2)mRNA 定量来检查 SLN 是否存在转移。根据 KRAS 和 BRAF 突变状态以及原发肿瘤中的微卫星不稳定性状态对患者进行分层。通过 Kaplan-Meier 生存估计和对数秩检验分析生存终点。
在 213 例纳入的患者中的 206 例(97%)中确定了总共 817 个 SLN。SLN 和其他区域淋巴结的常规组织学检查确定了 63 例阳性淋巴结(pN+)患者,其中 42 例(67%)在一个或多个 SLN 中呈阳性(敏感性 67%,假阴性率 33%)。根据 SLN 中 CK20 和 MUC2 mRNA 水平,在 143 例其他淋巴结阴性(pN0)患者中,分别有 86 例(60%)和 52 例(36%)提示隐匿性转移。中位随访 3.6 年后的生存分析显示,MUC2 mRNA 定量在所有患者的 SLN 中均具有显著的预后价值;然而,隐匿性 SLN 转移检测并没有。
通过 CK20 和 MUC2 mRNA 定量检测到的隐匿性 SLN 转移具有有限的预后价值。